No selective 5-HT7 agonists are available for clinical use
There is an apparent causal link between constitutive 5-HT7 receptor activity and pathological aggregation of tau protein, associated with Alzheimer’s disease or frontotemporal dementia. Serotonergic mechanisms have not been implicated with increased dementia risk.
Drugs with this mechanism (1)
Serotonin — The endogenous ligand at fourteen receptor subtypes; the home of serotonicity — synaptic serotonin elevation.
Self-check
What timing process does 5-HT7 agonism modulate? Circadian phase.
Are selective 5-HT7 agonists available for clinical use in this source? No.